CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc., trading under the ticker PBAX on Nasdaq, is the successor entity to Phoenix Biotech Acquisition Corp, a blank-check company that completed its IPO in 2021 targeting the healthcare and life sciences sector. The SPAC, sponsored by Phoenix Biotech Sponsor LLC, pursued a business combination with Cero Therapeutics, a clinical-stage biopharmaceutical company developing chimeric engulfment receptor T cell therapies for oncology indications. The 10-K filed March 24, 2023, with accession number 0001193125-23-078172, reflects the company's annual reporting obligations following the de-SPAC transaction. For complete filing history, sponsor details, and deal timeline on PBAX and hundreds of other SPACs, sign up for full data access at SpacDesk.